Molecular and Cellular Biology, May 2009, p. 2335-2345, Vol. 29, No. 9
0270-7306/09/$08.00+0 doi:10.1128/MCB.00687-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Christina M. H. Powell,1,
Jill K. Fecko,1
Roxanne Cacioppo,1,
Hubert S. Chou,2,
Geoffrey M. Cooper,1 and
Ulla Hansen1*
Department of Biology, Boston University, Boston, Massachusetts 02215,1 Harvard Medical School and Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts 021292
Received 27 April 2008/ Returned for modification 19 May 2008/ Accepted 10 February 2009
Transcription factor LSF is required for progression from quiescence through the cell cycle, regulating thymidylate synthase (Tyms) expression at the G1/S boundary. Given the constant level of LSF protein from G0 through S, we investigated whether LSF is regulated by phosphorylation in G1. In vitro, LSF is phosphorylated by cyclin E/cyclin-dependent kinase 2 (CDK2), cyclin C/CDK2, and cyclin C/CDK3, predominantly on S309. Phosphorylation of LSF on S309 is maximal 1 to 2 h after mitogenic stimulation of quiescent mouse fibroblasts. This phosphorylation is mediated by cyclin C-dependent kinases, as shown by coimmunoprecipitation of LSF and cyclin C in early G1 and by abrogation of LSF S309 phosphorylation upon suppression of cyclin C with short interfering RNA. Although mouse fibroblasts lack functional CDK3 (the partner of cyclin C in early G1 in human cells), CDK2 compensates for this absence. By transient transfection assays, phosphorylation at S309, mediated by cyclin C overexpression, inhibits LSF transactivation. Moreover, overexpression of cyclin C and CDK3 inhibits induction of endogenous Tyms expression at the G1/S transition. These results identify LSF as only the second known target (in addition to pRb) of cyclin C/CDK activity during progression from quiescence to early G1. Unexpectedly, this phosphorylation prevents induction of LSF target genes until late G1.
Published ahead of print on 23 February 2009.
These authors contributed equally to this work.
Present address: Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, MA 02139.
Present address: Daiichi-Sankyo Pharma Development, 339 Thornall Street, Edison, NJ 08837.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»